Abstract
Despite significant scientific interest, only a small number of inhaled biologics have reached regulatory approval, reflecting the complex interplay between the inherent structural fragility of biologics during the aerosolization steps intrinsic to inhaled administration and the absence of inhalation-specific regulatory guidance. This review examines the key scientific and technical considerations that influence the stability, safety, and performance of inhaled biologics, including aggregation, chemical degradation, immunogenicity, device compatibility, and the limited availability of inhalation-qualified excipients.
Existing regulatory frameworks in the United States and Europe for biological products, inhalation products, and delivery devices provide substantial foundations for inhaled biologic development. Their application requires an integrated assessment of the final formulation–device pairing, particularly where aerosolization alters molecular integrity, biological activity, or pulmonary exposure.
This review connects these considerations with clinical experience and proposes a scope for dedicated guidance addressing quality, pulmonary safety, device performance, and clinical benefit. A survey of ongoing clinical trials reveals a growing but constrained pipeline dominated by mRNA therapeutics, protein-based agents, and viral-vectored vaccines, underscoring both progress and persistent formulation barriers. Together, these insights emphasize the urgent need for a harmonized regulatory paradigm tailored to inhaled biologics that integrates biologic-specific analytical expectations, aerosolization stress testing, and clear pathways for excipient qualification.
Introduction
FDA guidance on immunogenicity assessment for therapeutic protein products indicates that the inhalational route of administration may be associated with increased immunogenicity compared to intramuscular and intravenous (IV) routes [1]. Pulmonary delivery of different biological products has gained significant interest in the past decade owing to its non-invasive nature and potential to limit off target effects among other potential benefits [2], [3]. This interest has resulted in many inhaled biologics to be evaluated in clinical trials, however only four biological products have been listed in purple book and approved for use by inhalation route [4]. This observation, combined with the recent increased interest in developing inhaled biologic products, highlights the need to better understand the safety and toxicity testing of inhaled biologics.
Fig. 1 demonstrates some of the issues encountered with safety and toxicity testing of inhaled biologics these range from issues of immunogenicity, aggregation, long-term effects, and side effects like post-inhalation cough. For the purpose of this contribution, the term “biologic” and “biological product” are used interchangeably and the FDA definition of “Biological products include a wide range of products such as vaccines, blood and blood components, allergenics, somatic cells, gene therapy, tissues, and recombinant therapeutic proteins” is adopted [5]. Biologics can be composed of sugars, proteins, or nucleic acids or complex combinations of these substances, or may be living entities such as cells and tissues [5].
Emerging modalities such as mRNA therapeutics, viral-vectored vaccines, recombinant enzymes, and antibody fragments underscore the need for a clearer scientific and regulatory foundation for inhaled biologics [6], [7]. These systems often exhibit pronounced sensitivity to aerosolization, where exposure to interfacial stress, shear forces, and dehydration can promote unfolding, aggregation, chemical modification, or loss of activity [8]. Such changes may affect potency, pharmacokinetics, and can influence immune recognition within the lung. These challenges are compounded by the structural and cellular features of the respiratory tract, which impose additional constraints on stability and deposition and require formulation and device strategies that account for both biologic-specific and inhalation-specific vulnerabilities [9], [10].
Despite advances in formulation science and device engineering, the regulatory landscape for inhaled biologics remains complex. Inhalation-specific guidance has historically been developed for small-molecule products, emphasizing aerodynamic performance and device robustness. Guidance for biologics focuses on structural characterization, product heterogeneity, and immunogenicity risk. When a biologic is administered via the pulmonary route, these two regulatory paradigms intersect offering a complex framework for addressing aerosol-induced structural changes, excipient justification, impurity control, or the device–product interface. These disparate guidances may contribute to uncertainty in defining critical quality attributes, appropriate analytical methods, and acceptable safety margins for biologics intended for inhalation. Regulatory agencies must evaluate whether the complete product can be manufactured consistently and used safely and effectively. For an inhaled biologic, this requires a product-specific assessment of the biologic, formulation, delivery device, and their interactions during storage, aerosolization, and patient use. Relevant evidence may include structural integrity and potency after delivery, aerosol performance, local pulmonary safety, device reliability, and usability. The studies needed to address these risks will vary with the modality, indication, dosing regimen, and device configuration.
Growing interest in inhaled biologics is also demonstrated by a few relevant reviews published during the preparation of this manuscript. Cipolla et al. discussed how existing guidance for biologics, inhalation products, and combination products can be applied to inhaled and nasal therapies, using examples involving peptides, a marketed inhaled biologic, and viral-based products [11]. Singh and Hickey examined the development of locally acting inhaled proteins in Part I; Part II addressed their characterization, including delivered-dose uniformity, aerodynamic particle size distribution, device robustness, stability, and specifications [12], [13]. Against this background, the present review examines pulmonary safety and toxicity across the product lifecycle, with particular attention to immunogenicity, aggregation, excipient and impurity exposure, and interactions between the biologic and its delivery device. A survey of 81 identified clinical trials places these risks in the context of current development activity, while the Exubera and Pulmozyme case studies examine how product design, safety evaluation, and use considerations have played out in approved products. Building on these analyses, the review also considers how aerosolization-related changes in molecular integrity and biological activity inform regulatory assessment and proposes a framework integrating quality characterization, nonclinical safety, clinical evaluation, and lifecycle management.
The current study aims to discuss some of the important considerations and regulations associated with the safety and toxicity evaluation of inhaled biologics. This work is structured as follows. In Section 2 we review some important considerations to account for and address in inhaled biological products formulations. These include discussion on the influence of immunogenicity, aggregation, excipient use, device considerations and impurities. In Section 3, the current official regulations surrounding the regulatory pathways for inhaled biologics are highlighted. Section 5 highlights products that are currently approved and in clinical trials.
Continue reading here
Ishaan Duggal, Zachary Warnken, Varsha Nair, Alan Watts, Nicholas Peppas, Hugh Smyth, Regulatory landscape for inhaled biologics: Considerations and guidelines, Advanced Drug Delivery Reviews, 2026, 115986, ISSN 0169-409X, https://doi.org/10.1016/j.addr.2026.115986.
Did you missed our webinar, watch it here for free:
Developing Reliable Capsule-Based Dry Powder Inhalers












































All4Nutra







